U.S. FDA Approval of Rybrevant Faspro Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen When Combined With Lazcluze
December 18, 2025
December 18, 2025
RARITAN, New Jersey, Dec. 18 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
U.S. FDA Approval of RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE(R) (lazertinib)
RYBREVANT FASPRO(TM), the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hour . . .
* * *
U.S. FDA Approval of RYBREVANT FASPRO(TM) (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE(R) (lazertinib)
RYBREVANT FASPRO(TM), the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hour . . .